Fractyl Health (NASDAQ:GUTS) Issues Earnings Results

Fractyl Health (NASDAQ:GUTS) issued its quarterly earnings results on Tuesday. The company reported ($0.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.13), reports.

Here are the key takeaways from Fractyl Health’s conference call:

• Post‑hoc dose‑response analysis shows longer duodenal ablation (>14–16 cm) strongly correlates with weight‑maintenance; in the optimized subgroup Revita patients regained 2.9% vs 9.9% for sham at six months (≈70% reduction in regain).
• The REMAIN‑1 pivotal is fully randomized with >300 participants across 30+ sites, two pre‑specified co‑primary endpoints and >90% power, with topline six‑month randomized data expected in early Q4 2026.
• FDA feedback indicated Revita’s safety profile is consistent with a moderate‑risk de novo classification, and the company plans a de novo submission in late Q4 2026, a faster and more capital‑efficient pathway than a PMA.
• Cash and equivalents of ~$81.5M (plus $4.1M received post‑period) are expected to fund operations into early 2027, and management has closed the ATM and does not plan a capital raise before pivotal data, creating a narrow financing runway if timelines slip.
• The Rejuva smart GLP‑1 program is progressing (CTAs filed in EU/Australia) with potential first‑in‑human dosing and preliminary data in H2 2026; it is being advanced under a disciplined budget and will not compete with Revita for capital.

Fractyl Health Stock Down 3.5%

GUTS opened at $0.43 on Wednesday. The firm has a market cap of $58.98 million, a PE ratio of -0.19 and a beta of 1.51. The business has a fifty day simple moving average of $0.80 and a 200-day simple moving average of $1.29. Fractyl Health has a fifty-two week low of $0.38 and a fifty-two week high of $3.03.

Fractyl Health News Roundup

Here are the key news stories impacting Fractyl Health this week:

• Positive Sentiment: Company highlighted ongoing Revita development progress, which supports long‑term value if clinical/regulatory milestones continue to advance. Fractyl Highlights Revita Progress and 2025 Financial Results
• Neutral Sentiment: Earnings call transcript is available for investors who want full management commentary and Q&A to assess the company’s cash runway and strategic actions. Q4 2025 Earnings Call Transcript
• Neutral Sentiment: Company filed a formal press release detailing Q4 and FY2025 results and business updates; review the release for GAAP/non‑GAAP metrics and any guidance or cash‑flow commentary. Press Release — Business Insider
• Negative Sentiment: Q4 EPS came in at ($0.32) vs. consensus (~($0.19)), a notable miss that pressured the stock as it increases near‑term financing concerns. Earnings Call Highlights — Yahoo Finance
• Negative Sentiment: Management explicitly discussed navigating financial challenges on the call/press release, which raises investor focus on cash runway, potential dilution, or the need for financing. Earnings Call Highlights — Yahoo Finance
• Neutral Sentiment: Short‑interest reporting is inconsistent across data feeds: an earlier March 13 report showed short interest down to ~5.83M shares (~5.8% of shares outstanding), but multiple subsequent feeds show anomalous “0 shares” figures — treat recent short‑interest data as unreliable until confirmed. (No single authoritative link available due to conflicting reports.)

Wall Street Analyst Weigh In

Several analysts have recently weighed in on GUTS shares. Weiss Ratings restated a “sell (d-)” rating on shares of Fractyl Health in a report on Monday, December 29th. Morgan Stanley cut shares of Fractyl Health from an “overweight” rating to an “equal weight” rating and dropped their price target for the stock from $8.00 to $2.00 in a research report on Thursday, January 29th. Canaccord Genuity Group reissued a “buy” rating and issued a $8.00 price target on shares of Fractyl Health in a report on Friday, December 19th. Finally, HC Wainwright restated a “buy” rating and set a $8.00 price objective on shares of Fractyl Health in a research report on Tuesday, December 2nd. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $5.40.

Institutional Investors Weigh In On Fractyl Health

Hedge funds have recently modified their holdings of the stock. Virtu Financial LLC purchased a new position in Fractyl Health in the 4th quarter worth about $153,000. Susquehanna Portfolio Strategies LLC purchased a new stake in Fractyl Health during the fourth quarter valued at about $108,000. Quadrature Capital Ltd boosted its holdings in shares of Fractyl Health by 2,047.1% in the fourth quarter. Quadrature Capital Ltd now owns 290,714 shares of the company’s stock worth $640,000 after buying an additional 277,174 shares during the period. Millennium Management LLC increased its position in shares of Fractyl Health by 356.6% in the fourth quarter. Millennium Management LLC now owns 1,861,418 shares of the company’s stock worth $4,095,000 after acquiring an additional 1,453,751 shares in the last quarter. Finally, Balyasny Asset Management L.P. purchased a new position in shares of Fractyl Health in the fourth quarter worth approximately $132,000.

Fractyl Health Company Profile

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.